trending Market Intelligence /marketintelligence/en/news-insights/trending/rQLyl1rqAROIQ7PIggOeug2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

NICE rejects Roche's skin cancer drug, gives conditional nod to Bayer treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

NICE rejects Roche's skin cancer drug, gives conditional nod to Bayer treatment

The U.K.'s National Institute for Health and Care Excellence, or NICE, did not recommend Roche Holding AG's Erivedge for use within the National Health Service.

The regulator said there was not enough evidence that demonstrated Erivedge, or vismodegib, was cost effective and better than existing therapies for metastatic basal cell carcinoma, a type of skin cancer.

As a result, the drug did not meet the criteria to be considered a life-extending end-of-life treatment.

Meanwhile, the regulator gave a conditional nod to Bayer AG's Stivarga for treating unresectable or metastatic gastrointestinal stromal tumors.

The drug will be available for patients with an eastern cooperative oncology group performance status of zero or one, meaning they must either be able to carry on all pre-disease performance without restriction or carry out work of a light or sedentary nature.